Abstract
We evaluated the efficacy, safety, and tolerance of cefotaxime in 35 adults (25 with pleuropulmonary infections, 7 with genitourinary tract infections, and 3 with soft tissue infections). Of these 35 patients, 18 (51.4%) were seriously or critically ill. In vitro susceptibility testing revealed that 90.4% of the pathogens isolated were susceptible to cefotaxime (minimal inhibitory concentration, less than 8 micrograms/ml), 4.8% were intermediately susceptible (minimal inhibitory concentration, 8 to 32 micrograms/ml), and 4.8% were resistant (minimal inhibitory concentration, greater than 32 micrograms/ml). A total of 34 of the 35 patients (97%) were clinically and bacteriologically cured of their infections. Adverse reactions occurred in two patients, but these reactions did not require interruption of therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adams H. G., Stilwell G. A., Turck M. In vitro evaluation of cefoxitin and cefamandole. Antimicrob Agents Chemother. 1976 Jun;9(6):1019–1024. doi: 10.1128/aac.9.6.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Belohradsky B. H., Bruch K., Geiss D., Kafetzis D., Marget W., Peters G. Intravenous cefotaxime in children with bacterial meningitis. Lancet. 1980 Jan 12;1(8159):61–63. doi: 10.1016/s0140-6736(80)90491-2. [DOI] [PubMed] [Google Scholar]
- Counts G. W., Turck M. Antibacterial activity of a new parenteral cephalosporin--HR 756: comparison with cefamandole and ceforanide. Antimicrob Agents Chemother. 1979 Jul;16(1):64–68. doi: 10.1128/aac.16.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dabernat H. J., Buu-Hoï-Dang Van A., Delmas C., Bauriaud R. Comparative activities of cefotaxime, a new cephalosporin derivative, and of selected beta-lactam antibiotics against Haemophilus species. Ann Microbiol (Paris) 1979 May-Jun;130 A(4):461–467. [PubMed] [Google Scholar]
- Drasar F. A., Farrell W., Howard A. J., Hince C., Leung T., Williams J. D. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods. J Antimicrob Chemother. 1978 Sep;4(5):445–450. doi: 10.1093/jac/4.5.445. [DOI] [PubMed] [Google Scholar]
- Findell C. M., Sherris J. C. Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance. Antimicrob Agents Chemother. 1976 Jun;9(6):970–974. doi: 10.1128/aac.9.6.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fu K. P., Neu H. C. The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) 1979 Sep;32(9):909–914. doi: 10.7164/antibiotics.32.909. [DOI] [PubMed] [Google Scholar]
- Hamilton-Miller J. M., Brumfitt W., Reynolds A. V. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. J Antimicrob Chemother. 1978 Sep;4(5):437–444. doi: 10.1093/jac/4.5.437. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Aswapokee N., Aswapokee P., Fu K. P. HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1979 Feb;15(2):273–281. doi: 10.1128/aac.15.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pechère J. C., Guay R., Dubois J., Letarte R. Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother. 1980 Jun;17(6):1001–1003. doi: 10.1128/aac.17.6.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sosna J. P., Murray P. R., Medoff G. Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother. 1978 Dec;14(6):876–879. doi: 10.1128/aac.14.6.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilkins T. D., Thiel T. Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother. 1973 Mar;3(3):350–356. doi: 10.1128/aac.3.3.350. [DOI] [PMC free article] [PubMed] [Google Scholar]